We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Fusion Antibodies Plc | FAB | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.40 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.40 | 3.40 | 3.40 | 3.40 | 3.40 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 23/7/2024 15:23 by gtc1508 Certainly looks that way. The Q1 trading udpdate was very positive also!There’s lots to be optimistic about with FAB. Truly believe it’s undervalued and the chart is suggesting we’re at the point of a Rerate. Any positive news and this flies up in my opinion. |
Posted at 23/7/2024 15:00 by thiopia 04/07/2024 Fusion Antibodies PLC Trading update18/07/2024 Fusion Antibodies PLC Launch of New Interactive Investor Hub 22/07/2024 Fusion Antibodies PLC Director/PDMR Shareholding Think they might be trying to tell us something? Something about business being #FAB maybe ? |
Posted at 17/7/2024 10:18 by maverick247 Why FAB is grossly undervalued at a £1.5m EVhttps://spongeshar |
Posted at 04/7/2024 07:50 by thiopia 4 July 2024Fusion Antibodies plc ("Fusion" or the "Company") Trading update Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides an update on trading, commercial and research progress. Highlights · Positive momentum through the first quarter of the current financial year ending 31 March 2025 ("Q1 FY2025"), including: o first OptiPhageTM contract for a non-human antibody species received in April 2024; o ongoing collaboration agreement with the National Cancer Institute ("NCI") for the use of OptiMAL®; o further purchase orders received under a master services agreement ("MSA") with a leading diagnostics company; o multiple therapeutics project running in parallel with a US based biotechnology client; and o an increasingly positive sentiment amongst the industry and client base. · Unaudited revenues for Q1 FY2025 of c. £522k (Q1 FY2024: £241k, FY2024: £1.14m) · Consistent and strong sales pipeline, with an order book at 30 June 2024 of approximately £0.7m. The order book includes a number of multi-stage projects for its clients and, subject to these projects progressing in line with expectations, revenue is expected to be recognised for all projects in the current order book in the current financial year. · The Company continues to carefully control its cash and, as set out at the time of the fundraise in February 2024, based on internal estimations the Company has a cash runway into the second quarter of calendar year 2025. The Company continues to seek to achieve cash neutrality during that timeframe. Entering into FY2025, Fusion had built an improved order book and was starting to benefit from its improved commercial strategy of additionally targeting diagnostics, fundamental research and veterinary medicine markets. The Board is pleased to confirm that the marked increase in the Company's sales opportunity pipeline, as reported in its full year trading update on 30 April 2024 has been maintained. The Company is continuing to progress a number of exciting developments, including but not limited to: · securing its first OptiPhageTM contract whereby Fusion will design a phage display library using the diversity principles behind the OptiMAL® library. · progressing the collaboration with the NCI for the use of OptiMAL® in the discovery of novel antibodies against targets selected by NCI post year end; · progressing the previously announced major projects in line with the agreed project plans; specifically, the $650,000 follow-on project under a collaborative research and development agreement with a US based biotechnology company that Fusion started working with in 2021 and the further £200,000 project announced on 23 May 2024; · progressing multiple further projects, covered by the respective purchase orders mentioned above, under the new MSA with a leading diagnostic company; and · ongoing progress of the AI/ML research project with Oxford University to develop software to predict antibody expression levels and aid in the design of antibody sequences which, if successful, could improve productivity and success for our clients in the long term. The board of directors of Fusion believe that these developments provide strong evidence that the Company's commercial and diversification strategies, together with the improving economic climate and client sentiment, provide continuing confidence for growth in the remainder of FY2025. Adrian Kinkaid, CEO of Fusion, commented: "We are on track and on plan. It is particularly encouraging to see the continuing improvement in revenue recognition rates which are supported by further new orders and work in progress. This validates our strategy and puts us on track to meet our plans to ensure that Fusion is not only sustainable but becomes the thriving business which it deserves to be." |
Posted at 03/7/2024 12:34 by jaknife soultrading,"Taken from company itself and broker notes. So factual based on info we currently have" If that's taken from a broker's note then that broker is either incompetent or bent (and has been paid to write optimistic nonsense). Let's go through the numbers slowly: 1. The recent trend of revenue performance is: 2020 £4.17m2021 £4.80m2022 £2.90m2023 £1.58m2024E £1.14m 2. The gross margin in the year to 31 March 2023 was 19.8% , let's assume that it comes in at a round 20% for the year to 31 March 2025. 3. Historic admin costs are in the ball park of £3m per annum. 4. Based on these numbers, this means that FAB needs to get to a revenue of c. £15m in order to just break even. Ie: (£k)Revenue £15,000Cost of sales £12,000Gross profit £ 3,000 (20%)Admin expenses £ 3,000 -------Profit for the period £ 0 You don't need to do anything more detailed than this to understand that: A. FAB need to get to a revenue of £15m in 2025 just to breakeven. B. IF FAB only get to a revenue of £7.5m then they will lose/burn £1.5m. Given the recent revenue trend and the lack of RNSs claiming huge contract wins then we can all safely assume that FAB is on target to make revenues materially less than £7.5m. Somewhere in the £2m range is probably optimistic. And, on that basis, FAB is going to run out of cash before Christmas! JakNife |
Posted at 03/7/2024 10:57 by jaknife soultrading,What complete garbage. For example: "They are fully funded into 2025 and like to be cash neutral to positive this year." Post 3,931 shows the fundamental numbers, FAB need to achieve revenue of c. £15.0 to reach breakeven when last year the revenue was only £1.14m and the biggest brag that the company has so far is that their have "an orderbook of £0.75m". There is not a hope in hell that FAB will be cash neutral this year. At current cash burn rates the cash will run out well before Christmas! JakNife |
Posted at 02/7/2024 20:10 by jaknife troutisout,I have DM'd you the Allenby broker forecasts. But my apologies my wording was imprecise, "in 20024" should be "in the year to 31 Dec 2024", there are no forecasts available beyond that. What words/numbers in the 30 April 2024 Year-end trading statement make you think that "FAB have turned a corner"? I note: "Significant increase in sales pipeline opportunities during H2 FY2024, with an orderbook at 31 March 2024 of £0.75m, representing 65 per cent. of total FY2024 unaudited revenues" However: 1. This was the first time that FAB published a number for their pipeline so it's impossible to tell if this represents an improvement on the prior period and hence evidence of having "turned a corner"? 2. The gross margin in the year to 31 March 2023 was 19.8% and admin costs are in the ball park of £3m per annum. That means that FAB has to get to a revenue of c. £15m in order to just break even. Ie: (£k)Revenue £15,000Cost of sales £12,000Gross profit £ 3,000 (20%)Admin expenses £ 3,000Profit for the period £ 0 I have assumed a 20% gross profit margin to keep the numbers simple. If FAB don't get to a revenue of £15m then they will make a loss in the year to 31 March 2025. Furthermore, if FAB don't get to half of that revenue number (£7,500k) then FAB will burn through their current cash and need to raise funds again. What forecast full-year revenue for 2025 do you infer from the 30 April 2024 Year-end trading statement? JakNife |
Posted at 02/7/2024 18:12 by troutisout "So current forecasts for 2024 are that revenue will be 28% *DOWN* on 2023 revenue, continuing a negative trend. Those same forecasts are for continued losses in 2024."Are you able to provide some evidence of current forecasts for continued losses in 2024??? Only FY 2024 ended at the end of March, the last few months are now FY2025, so you seem behind the curve and yes there is an Trading Update RNS from 30th April that suggests FAB have turned a corner and the last months of FY 2024 were the highest earning of that trading year. |
Posted at 02/7/2024 11:47 by jaknife bobaxe1,"Oversold company Turned a corner Should re rate" Do you have anything to demonstrate that FAB has "turned a corner"? It's just that I noted here a while ago that the recent trend of revenue performance is: 2020 £4.17m2021 £4.80m2022 £2.90m2023 £1.58m2024E £1.14m So current forecasts for 2024 are that revenue will be 28% *DOWN* on 2023 revenue, continuing a negative trend. Those same forecasts are for continued losses in 2024. Have I missed an RNS that demonstrates that FAB has "turned a corner"? Are forecasts for 2025 materially higher? Is 2025 finally going to be a profitable year? Where is the objective evidence please? JakNife |
Posted at 27/2/2024 10:31 by troutisout "Fusion Antibodies (FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announced it has received a first purchase order under the master services agreement (MSA) with a leading diagnostics company details of which were announced on 14 February 2024. FAB said reaching this agreement with a world class diagnostics provider positively reinforces the value to the wider commercial world of Fusion Antibodies’ technologies and capabilities. In this case it is the generation of antibodies in diagnostics products.Comment: It could be argued that fundamentally FAB is now on track as a recovery situation, with the purchase order and recent funding. Only a rise in the share price is missing." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
